

Medical Coverage Policy | Measurement of Exhaled Nitric Oxide and Exhaled Breath Condensate in the Diagnosis and Management of Respiratory Disorders



EFFECTIVE DATE: 03|03|2015

POLICY LAST UPDATED: 11|19|2025

OVERVIEW

Evaluation of exhaled nitric oxide (NO) and exhaled breath condensate (EBC) are proposed as techniques to diagnose and monitor asthma and other respiratory conditions. There are commercially available devices for measuring NO in expired breath and various laboratory techniques for evaluating components of EBC.

MEDICAL CRITERIA

Not applicable

PRIOR AUTHORIZATION

Not applicable

POLICY STATEMENT

Medicare Advantage Plans

Measurement of exhaled nitric oxide is not covered in the diagnosis and management of asthma, eosinophilic asthma, and other respiratory disorders including but not limited to chronic obstructive pulmonary disease and chronic cough as the evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Measurement of exhaled breath condensate is not covered in the diagnosis and management of asthma and other respiratory disorders including but not limited to chronic obstructive pulmonary disease and chronic cough as the evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Commercial Products

Measurement of exhaled nitric oxide is considered not medically necessary in the diagnosis and management of asthma, eosinophilic asthma, and other respiratory disorders including but not limited to chronic obstructive pulmonary disease and chronic cough as the evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Measurement of exhaled breath condensate is considered not medically necessary in the diagnosis and management of asthma and other respiratory disorders including but not limited to chronic obstructive pulmonary disease and chronic cough as the evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

COVERAGE

Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage or Subscriber Agreement for applicable not medically necessary/not covered benefits/coverage.

BACKGROUND

Asthma

Asthma is characterized by airway inflammation that leads to airway obstruction and hyper-responsiveness, which in turn lead to characteristic clinical symptoms including wheezing, shortness of breath, cough, and chest tightness. In the United States, the burden of asthma falls disproportionately on Black, Hispanic, and American Indian and Alaska Native populations. Asthma-related emergency department visits are nearly 5 times higher for Black patients when compared to White patients, and Black patients are nearly 3 times as likely to die from asthma when compared to White patients. Differences in life experiences (eg, family, social,

and economic environment), lifestyle choices (smoking, obesity, leisure-time physical activities), and exposure to adverse indoor and outdoor environment factors (e.g., mold, pollens, house dust mites, cockroaches, rodents, animal allergens, and other air pollutants) may account for some of the racial and ethnic differences in asthma prevalence. A gender disparity also exists in asthma prevalence – in children, asthma is more common in boys versus girls, whereas among adults, women are more likely than men to have an asthma diagnosis.

Management

Guidelines for the management of persistent asthma stress the importance of long-term suppression of inflammation using inhaled corticosteroids as primary treatment. Existing techniques for monitoring the status of underlying inflammation have focused on bronchoscopy, with lavage and biopsy, or analysis by induced sputum. Given the cumbersome nature of these techniques, the ongoing assessment of asthma focuses not on the status of the underlying chronic inflammation, but rather on regular assessments of respiratory parameters such as forced expiratory volume in 1 second and peak flow. Therefore, there has been an interest in noninvasive techniques to assess the underlying pathogenic chronic inflammation as reflected by measurements of inflammatory mediators.

Fractional Exhaled Nitric Oxide

One proposed strategy is the measurement of fractional exhaled nitric oxide (FeNO). Nitric oxide (NO) is an important endogenous messenger and inflammatory mediator that is widespread in the human body, with functions including the regulation of peripheral blood flow, platelet function, immune reactions, neurotransmission, and the mediation of inflammation. Patients with asthma have been found to have high levels of FeNO, which decreases with treatment with corticosteroids. In biologic tissues, NO is unstable, limiting measurement. However, in the gas phase, NO is fairly stable, permitting its measurement in exhaled air. FeNO is typically measured during single breath exhalations. First, the subject inspires NO-free air via a mouthpiece until total lung capacity is achieved, followed immediately by exhalation through the mouthpiece into the measuring device. Devices measuring FeNO are commercially available in the United States. According to a 2009 joint statement by the American Thoracic Society and European Respiratory Society, there is a consensus that FeNO is best measured at an exhaled rate of 50 mL per second maintained within 10% for more than 6 seconds at an oral pressure between 5 and 20 cm H₂O. Results are expressed as the NO concentration in parts per billion, based on the mean of 2 or 3 values.

Exhaled Breath Condensate

Exhaled breath condensate (EBC) consists of exhaled air passed through a condensing or cooling apparatus, resulting in an accumulation of fluid. Although EBC is primarily derived from water vapor, it also contains aerosol particles or respiratory fluid droplets, which in turn contain various nonvolatile inflammatory mediators, such as cytokines, leukotrienes, oxidants, antioxidants, and other markers of oxidative stress. There are a variety of laboratory techniques to measure the components of EBC, including such simple techniques as pH measurement and the more sophisticated gas chromatography/mass spectrometry or high-performance liquid chromatography, depending on the component of interest.

Clinical Uses of Fractional Exhaled Nitric Oxide and Exhaled Breath Condensate

Measurement of FeNO has been associated with an eosinophilic asthma phenotype. Eosinophilic asthma is a subtype of asthma associated with sputum and serum eosinophilia, along with later-onset asthma. Until recently, most asthma management strategies did not depend on the recognition or diagnosis of a particular subtype. However, anti-interleukin 5 inhibitors have been approved by the Food and Drug Administration (FDA) for the treatment of severe asthma with an eosinophilic phenotype. Anti-IL-4 receptor/anti-IL-13 monoclonal antibodies, anti-immunoglobulin E monoclonal antibodies, and thymic stromal lymphopoietin blocker monoclonal antibodies are also available to improve uncontrolled asthma that does not necessarily have an eosinophilic phenotype.

Measurement of NO and EBC has been investigated in the diagnosis and management of asthma. Potential management uses include assessing response to anti-inflammatory treatment, monitoring compliance with treatment, and predicting exacerbations. Aside from asthma, they have also been proposed in the

management of patients with chronic obstructive pulmonary disease, cystic fibrosis, allergic rhinitis, pulmonary hypertension, and primary ciliary dyskinesia.

For individuals who have suspected asthma who receive measurement of fractional exhaled nitric oxide (FeNO) for diagnosis, the evidence includes multiple retrospective and prospective studies of diagnostic accuracy, along with systematic reviews of those studies. Relevant outcomes are test validity, symptoms, change in disease status, morbid events, and functional outcomes. There are multiple reports on the sensitivity and specificity of FeNO in asthma diagnosis; however, most studies are in the setting of patients with asthma symptoms without previous testing (or with unclear previous testing), which is unlikely to be how the test is used in a U.S. setting. The available evidence is limited by variability in FeNO cutoff levels used to diagnose asthma, lack of data on performance characteristics in challenging diagnostic settings, and lack of data on the incremental value of adding FeNO to existing diagnostic algorithms from studies with concurrent controls. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have asthma who receive medication management directed by FeNO, the evidence includes diagnostic accuracy studies, multiple randomized controlled trials (RCTs) and systematic reviews of those trials. Relevant outcomes are symptoms, change in disease status, morbid events, and functional outcomes. The available RCTs evaluating the use of FeNO tests to guide step-up/step-down therapy in patients have not consistently found improvement in health outcomes. Two Cochrane reviews from 2016, one on adults and the other on children, found FeNO-guided asthma management to guide step-up/step-down therapy reduced the number of individuals who had more than 1 exacerbation in children but not in adults compared with guidelines-driven therapy. However, it had no impact on day-to-day symptoms or hospitalizations. Limitations of the published evidence preclude determining the effects of the technology on net health outcome. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have severe asthma who receive a measurement of FeNO to select treatment, the evidence includes diagnostic accuracy studies and subgroup analyses of RCTs and observational studies. Relevant outcomes are test validity, symptoms, change in disease status, morbid events, and functional outcomes. For the use of FeNO to identify eosinophilic asthma for the purpose of selecting patients for therapy with anti-interleukin (IL)-5 therapy or an anti-IL-4 receptor (IL-4R)/anti-IL-13 monoclonal antibody, subgroup analyses of RCTs are available. The evidence that points toward an interaction between baseline FeNO and treatment for the outcome of response suggests that there may be a quantitative but not necessarily a qualitative interaction between baseline FeNO and anti-IL-4R/anti-IL-13 treatment (dupilumab). Therefore, it is unclear if baseline FeNO can identify a group for whom there is no benefit from dupilumab. Similarly, a subgroup analysis for mepolizumab suggested a more pronounced effect compared to placebo in those with elevated levels of both blood eosinophils and FeNO. However, outcomes were not reported stratified based on FeNO alone precluding insight into the utility of using FeNO to predict response to treatment. For use of FeNO to predict response to therapy for patients with other severe asthma phenotypes, such as the allergic subtype, where anti-immunoglobulin E therapy is used, a subgroup analysis of a RCT is available. Subgroup analysis of omalizumab showed an association with more favorable outcomes in patients with high FeNO levels, but as with dupilumab, a qualitative interaction has not been established. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have suspected or confirmed respiratory disorders other than asthma who receive measurement of FeNO, the evidence includes a crossover trial, an open-label trial, a pilot study, and observational studies. Relevant outcomes are test validity, symptoms, change in disease status, morbid events, and functional outcomes. The available evidence assessing the use of FeNO for respiratory disorders other than asthma is limited by heterogeneity in the conditions evaluated and uncertainty about how the test fits in defined clinical management pathways. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have suspected or confirmed respiratory disorders who receive a measurement of EBC, the evidence includes observational studies reporting on the association between various EBC components and disease severity. Relevant outcomes are test validity, symptoms, change in disease status, morbid events, and functional outcomes. There is considerable variability in the particular EBC components measured and criteria for standardized measurements. Also, there is limited evidence on the use of EBC for determining asthma severity, diagnosing other respiratory conditions, or guiding treatment decisions for asthma or other respiratory conditions. The available published evidence does not support conclusions on the utility of EBC for any indication. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

CODING

Medicare Advantage Plans and Commercial Products

The following CPT codes are not covered for Medicare Advantage Plans and not medically necessary for Commercial Products:

- 83987** pH; exhaled breath condensate
- 95012** Nitric oxide expired gas determination

RELATED POLICIES

Not applicable

PUBLISHED

- Provider Update, January 2026
- Provider Update, October 2024
- Provider Update, August 2023
- Provider Update, November 2022
- Provider Update, March 2021

REFERENCES

1. Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. *Am J Respir Crit Care Med.* Jul 01 2009; 180(1): 59-99. PMID 19535666
2. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. *Eur Respir J.* Feb 2014; 43(2): 343-73. PMID 24337046
3. National Heart Lung and Blood Institute. Guidelines for the Diagnosis and Management of Asthma (EPR-3) 2007; <https://www.nhlbi.nih.gov/health-topics/guidelines-for-diagnosis-management-of-asthma>. Accessed April 29, 2025.
4. Bossuyt PM, Irwig L, Craig J, et al. Comparative accuracy: assessing new tests against existing diagnostic pathways. *BMJ.* May 06 2006; 332(7549): 1089-92. PMID 16675820
5. National Institute for Health and Care Excellence (NICE). Asthma: diagnosis, monitoring and chronic asthma management [NG80]. 2017. Updated 2021; <https://www.nice.org.uk/guidance/ng80>. Accessed April 30, 2025.
6. Harnan SE, Essat M, Gomersall T, et al. Exhaled nitric oxide in the diagnosis of asthma in adults: a systematic review. *Clin Exp Allergy.* Mar 2017; 47(3): 410-429. PMID 27906490
7. Karrasch S, Linde K, Rücker G, et al. Accuracy of FENO for diagnosing asthma: a systematic review. *Thorax.* Feb 2017; 72(2): 109-116. PMID 27388487
8. Wang Z, Pianosi PT, Keogh KA, et al. The Diagnostic Accuracy of Fractional Exhaled Nitric Oxide Testing in Asthma: A Systematic Review and Meta-analyses. *Mayo Clin Proc.* Feb 2018; 93(2): 191-198. PMID 29275031
9. Wang Z, Pianosi P, Keogh K, et al. The Clinical Utility of Fractional Exhaled Nitric Oxide (FeNO) in Asthma Management (Comparative Effectiveness Review No. 197). Rockville, MD: Agency for Healthcare Research and Quality; 2017.
10. Tang W, Zhou J, Miao L, et al. Clinical features in patients of cough variant asthma with normal and high level of exhaled fractional nitric oxide. *Clin Respir J.* Feb 2018; 12(2): 595-600. PMID 27731932

11. Engel J, van Kampen V, Lotz A, et al. An increase of fractional exhaled nitric oxide after specific inhalation challenge is highly predictive of occupational asthma. *Int Arch Occup Environ Health*. Oct 2018; 91(7): 799-809. PMID 29850946
12. Kim K, Cho HJ, Yoon JW, et al. Exhaled nitric oxide and mannitol test to predict exercise-induced bronchoconstriction. *Pediatr Int*. Aug 2018; 60(8): 691-696. PMID 29786927
13. Guo Z, Wang Y, Xing G, et al. Diagnostic accuracy of fractional exhaled nitric oxide in asthma: a systematic review and meta-analysis of prospective studies. *J Asthma*. 2016; 53(4): 404-12. PMID 26796787
14. Keßler A, Kragl U, Glass Ä, et al. Exhaled nitric oxide can't replace the methacholine challenge in suspected pediatric asthma. *Respir Med*. Oct 2019; 157: 21-25. PMID 31476569
15. Busse WW, Morgan WJ, Taggart V, et al. Asthma outcomes workshop: overview. *J Allergy Clin Immunol*. Mar 2012; 129(3 Suppl): S1-8. PMID 22386504
16. Fuhlbrigge A, Peden D, Apter AJ, et al. Asthma outcomes: exacerbations. *J Allergy Clin Immunol*. Mar 2012; 129(3 Suppl): S34-48. PMID 22386508
17. Cloutier MM, Schatz M, Castro M, et al. Asthma outcomes: composite scores of asthma control. *J Allergy Clin Immunol*. Mar 2012; 129(3 Suppl): S24-33. PMID 22386507
18. Juniper EF, Svensson K, Mörk AC, et al. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. *Respir Med*. May 2005; 99(5): 553-8. PMID 15823451
19. Schatz M, Zeiger RS, Zhang F, et al. Development and preliminary validation of the Asthma Intensity Manifestations Score (AIMS) derived from Asthma Control Test, FEV(1), fractional exhaled nitric oxide, and step therapy assessments. *J Asthma*. Mar 2012; 49(2): 172-7. PMID 22304003
20. Petsky HL, Kew KM, Turner C, et al. Exhaled nitric oxide levels to guide treatment for adults with asthma. *Cochrane Database Syst Rev*. Sep 01 2016; 9(9): CD011440. PMID 27580628
21. Korevaar DA, Damen JA, Heus P, et al. Effectiveness of FeNO-guided treatment in adult asthma patients: A systematic review and meta-analysis. *Clin Exp Allergy*. Aug 2023; 53(8): 798-808. PMID 37293870
22. Tsurumaki H, Abe Y, Oishi K, et al. Assessing the utility of fractional exhaled nitric oxide-guided management in adult patients with asthma: A systematic review and meta-analysis. *Respir Investig*. Jan 2025; 63(1): 118-126. PMID 39689589
23. Petsky HL, Kew KM, Chang AB. Exhaled nitric oxide levels to guide treatment for children with asthma. *Cochrane Database Syst Rev*. Nov 09 2016; 11(11): CD011439. PMID 27825189
24. Petsky HL, Cates CJ, Kew KM, et al. Tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils): a systematic review and meta-analysis. *Thorax*. Dec 2018; 73(12): 1110-1119. PMID 29858277
25. Szeffler SJ, Mitchell H, Sorkness CA, et al. Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial. *Lancet*. Sep 20 2008; 372(9643): 1065-72. PMID 18805335
26. Turner S, Cotton S, Wood J, et al. Reducing asthma attacks in children using exhaled nitric oxide (RAACENO) as a biomarker to inform treatment strategy: a multicentre, parallel, randomised, controlled, phase 3 trial. *Lancet Respir Med*. Jun 2022; 10(6): 584-592. PMID 35101183
27. Heaney LG, Busby J, Hanratty CE, et al. Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial. *Lancet Respir Med*. Jan 2021; 9(1): 57-68. PMID 32916135
28. Calhoun WJ, Ameredes BT, King TS, et al. Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: the BASALT randomized controlled trial. *JAMA*. Sep 12 2012; 308(10): 987-97. PMID 22968888
29. Hashimoto S, Brinke AT, Roldaan AC, et al. Internet-based tapering of oral corticosteroids in severe asthma: a pragmatic randomised controlled trial. *Thorax*. Jun 2011; 66(6): 514-20. PMID 21474498
30. Shaw DE, Berry MA, Thomas M, et al. The use of exhaled nitric oxide to guide asthma management: a randomized controlled trial. *Am J Respir Crit Care Med*. Aug 01 2007; 176(3): 231-7. PMID 17496226
31. Smith AD, Cowan JO, Brassett KP, et al. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. *N Engl J Med*. May 26 2005; 352(21): 2163-73. PMID 15914548
32. Peirsman EJ, Carvelli TJ, Hage PY, et al. Exhaled nitric oxide in childhood allergic asthma management: a randomised controlled trial. *Pediatr Pulmonol*. Jul 2014; 49(7): 624-31. PMID 24039119

33. Pike K, Selby A, Price S, et al. Exhaled nitric oxide monitoring does not reduce exacerbation frequency or inhaled corticosteroid dose in paediatric asthma: a randomised controlled trial. *Clin Respir J*. Apr 2013; 7(2): 204-13. PMID 22747899
34. Verini M, Consilvio NP, Di Pillo S, et al. FeNO as a Marker of Airways Inflammation: The Possible Implications in Childhood Asthma Management. *J Allergy (Cairo)*. 2010; 2010. PMID 20948878
35. Fritsch M, Uxa S, Horak F, et al. Exhaled nitric oxide in the management of childhood asthma: a prospective 6-months study. *Pediatr Pulmonol*. Sep 2006; 41(9): 855-62. PMID 16850457
36. Szeffler SJ, Martin RJ, King TS, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. *J Allergy Clin Immunol*. Mar 2002; 109(3): 410-8. PMID 11897984
37. Smith AD, Cowan JO, Brassett KP, et al. Exhaled nitric oxide: a predictor of steroid response. *Am J Respir Crit Care Med*. Aug 15 2005; 172(4): 453-9. PMID 15901605
38. Knuffman JE, Sorkness CA, Lemanske RF, et al. Phenotypic predictors of long-term response to inhaled corticosteroid and leukotriene modifier therapies in pediatric asthma. *J Allergy Clin Immunol*. Feb 2009; 123(2): 411-6. PMID 19121860
39. Anderson WJ, Short PM, Williamson PA, et al. Inhaled corticosteroid dose response using domiciliary exhaled nitric oxide in persistent asthma: the FENOtype trial. *Chest*. Dec 2012; 142(6): 1553-1561. PMID 23364390
40. Visitsunthorn N, Prottasan P, Jirapongsananuruk O, et al. Is fractional exhaled nitric oxide (FeNO) associated with asthma control in children?. *Asian Pac J Allergy Immunol*. Sep 2014; 32(3): 218-25. PMID 25268339
41. Wilson E, McKeever T, Hargadon B, et al. Exhaled nitric oxide and inhaled corticosteroid dose reduction in asthma: a cohort study. *Eur Respir J*. Dec 2014; 44(6): 1705-7. PMID 25142486
42. Phipatanakul W, Mauger DT, Sorkness RL, et al. Effects of Age and Disease Severity on Systemic Corticosteroid Responses in Asthma. *Am J Respir Crit Care Med*. Jun 01 2017; 195(11): 1439-1448. PMID 27967215
43. Price DB, Buhl R, Chan A, et al. Fractional exhaled nitric oxide as a predictor of response to inhaled corticosteroids in patients with non-specific respiratory symptoms and insignificant bronchodilator reversibility: a randomised controlled trial. *Lancet Respir Med*. Jan 2018; 6(1): 29-39. PMID 29108938
44. Korevaar DA, Westerhof GA, Wang J, et al. Diagnostic accuracy of minimally invasive markers for detection of airway eosinophilia in asthma: a systematic review and meta-analysis. *Lancet Respir Med*. Apr 2015; 3(4): 290-300. PMID 25801413
45. Gao J, Wu F. Association between fractional exhaled nitric oxide, sputum induction and peripheral blood eosinophil in uncontrolled asthma. *Allergy Asthma Clin Immunol*. 2018; 14: 21. PMID 29796021
46. Kroes JA, Zielhuis SW, van Roon EN, et al. Prediction of response to biological treatment with monoclonal antibodies in severe asthma. *Biochem Pharmacol*. Sep 2020; 179: 113978. PMID 32305434
47. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. *Lancet*. Aug 18 2012; 380(9842): 651-9. PMID 22901886
48. Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. *N Engl J Med*. Sep 25 2014; 371(13): 1198-207. PMID 25199059
49. Ortega HG, Yancey SW, Mayer B, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. *Lancet Respir Med*. Jul 2016; 4(7): 549-556. PMID 27177493
50. Shrimanker R, Keene O, Hynes G, et al. Prognostic and Predictive Value of Blood Eosinophil Count, Fractional Exhaled Nitric Oxide, and Their Combination in Severe Asthma: A Post Hoc Analysis. *Am J Respir Crit Care Med*. Nov 15 2019; 200(10): 1308-1312. PMID 31298922
51. Castro M, Corren J, Pavord ID, et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. *N Engl J Med*. Jun 28 2018; 378(26): 2486-2496. PMID 29782217
52. Rabe KF, Nair P, Brusselle G, et al. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. *N Engl J Med*. Jun 28 2018; 378(26): 2475-2485. PMID 29782224
53. Pavord ID, Deniz Y, Corren J, et al. Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-to-Severe Asthma. *J Allergy Clin Immunol Pract*. Apr 2023; 11(4): 1213-1220.e2. PMID 36535524

54. Global Strategy for Asthma Management and Prevention (GINA). 2023; <https://ginasthma.org/reports/>. Accessed May 7, 2025.
55. Hanania NA, Alpan O, Hamilos DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. *Ann Intern Med.* May 03 2011; 154(9): 573-82. PMID 21536936
56. Hanania NA, Wenzel S, Rosén K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. *Am J Respir Crit Care Med.* Apr 15 2013; 187(8): 804-11. PMID 23471469
57. Casale TB, Luskin AT, Busse W, et al. Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study. *J Allergy Clin Immunol Pract.* Jan 2019; 7(1): 156-164.e1. PMID 29800752
58. Vincken S, Sylvia V, Daniel S, et al. The role of FeNO in stable COPD patients with eosinophilic airway inflammation. *Respir Med.* May 2021; 181: 106377. PMID 33838525
59. Tang B, Huang D, Wang J, et al. Relationship of Blood Eosinophils with Fractional Exhaled Nitric Oxide and Pulmonary Function Parameters in Chronic Obstructive Pulmonary Disease (COPD) Exacerbation. *Med Sci Monit.* Mar 12 2020; 26: e921182. PMID 32161254
60. Gao J, Zhang M, Zhou L, et al. Correlation between fractional exhaled nitric oxide and sputum eosinophilia in exacerbations of COPD. *Int J Chron Obstruct Pulmon Dis.* 2017; 12: 1287-1293. PMID 28490872
61. Chou KT, Su KC, Huang SF, et al. Exhaled nitric oxide predicts eosinophilic airway inflammation in COPD. *Lung.* Aug 2014; 192(4): 499-504. PMID 24816967
62. Oishi K, Hirano T, Suetake R, et al. Exhaled nitric oxide measurements in patients with acute-onset interstitial lung disease. *J Breath Res.* Jun 29 2017; 11(3): 036001. PMID 28660859
63. Guilleminault L, Saint-Hilaire A, Favelle O, et al. Can exhaled nitric oxide differentiate causes of pulmonary fibrosis?. *Respir Med.* Nov 2013; 107(11): 1789-96. PMID 24011803
64. Boon M, Meyts I, Proesmans M, et al. Diagnostic accuracy of nitric oxide measurements to detect primary ciliary dyskinesia. *Eur J Clin Invest.* May 2014; 44(5): 477-85. PMID 24597492
65. Su KC, Ko HK, Hsiao YH, et al. Fractional Exhaled Nitric Oxide Guided-Therapy in Chronic Obstructive Pulmonary Disease: A Stratified, Randomized, Controlled Trial. *Arch Bronconeumol.* Aug 2022; 58(8): 601-610. PMID 35312525
66. Dummer JF, Epton MJ, Cowan JO, et al. Predicting corticosteroid response in chronic obstructive pulmonary disease using exhaled nitric oxide. *Am J Respir Crit Care Med.* Nov 01 2009; 180(9): 846-52. PMID 19661244
67. Prieto L, Bruno L, Gutiérrez V, et al. Airway responsiveness to adenosine 5'-monophosphate and exhaled nitric oxide measurements: predictive value as markers for reducing the dose of inhaled corticosteroids in asthmatic subjects. *Chest.* Oct 2003; 124(4): 1325-33. PMID 14555562
68. Kunisaki KM, Rice KL, Janoff EN, et al. Exhaled nitric oxide, systemic inflammation, and the spirometric response to inhaled fluticasone propionate in severe chronic obstructive pulmonary disease: a prospective study. *Ther Adv Respir Dis.* Apr 2008; 2(2): 55-64. PMID 19124359
69. Davis MD, Montpetit A, Hunt J. Exhaled breath condensate: an overview. *Immunol Allergy Clin North Am.* Aug 2012; 32(3): 363-75. PMID 22877615
70. Effros RM, Su J, Casaburi R, et al. Utility of exhaled breath condensates in chronic obstructive pulmonary disease: a critical review. *Curr Opin Pulm Med.* Mar 2005; 11(2): 135-9. PMID 15699785
71. Hunt J. Exhaled breath condensate: an overview. *Immunol Allergy Clin North Am.* Nov 2007; 27(4): 587-96; v. PMID 17996577
72. Kazani S, Israel E. Exhaled breath condensates in asthma: diagnostic and therapeutic implications. *J Breath Res.* Dec 2010; 4(4): 047001. PMID 21383487
73. Liu J, Thomas PS. Exhaled breath condensate as a method of sampling airway nitric oxide and other markers of inflammation. *Med Sci Monit.* Aug 2005; 11(8): MT53-62. PMID 16049390
74. Thomas PS, Lowe AJ, Samarasinghe P, et al. Exhaled breath condensate in pediatric asthma: promising new advance or pouring cold water on a lot of hot air? a systematic review. *Pediatr Pulmonol.* May 2013; 48(5): 419-42. PMID 23401497

75. Aldakheel FM, Thomas PS, Bourke JE, et al. Relationships between adult asthma and oxidative stress markers and pH in exhaled breath condensate: a systematic review. *Allergy*. Jun 2016; 71(6): 741-57. PMID 26896172
76. Liu L, Teague WG, Erzurum S, et al. Determinants of exhaled breath condensate pH in a large population with asthma. *Chest*. Feb 2011; 139(2): 328-336. PMID 20966042
77. Navratil M, Plavec D, Erceg D, et al. Urates in exhaled breath condensate as a biomarker of control in childhood asthma. *J Asthma*. Jun 2015; 52(5): 437-46. PMID 25387148
78. Antus B, Barta I, Kullmann T, et al. Assessment of exhaled breath condensate pH in exacerbations of asthma and chronic obstructive pulmonary disease: A longitudinal study. *Am J Respir Crit Care Med*. Dec 15 2010; 182(12): 1492-7. PMID 20656939
79. Dinakar C, Chipps BE, Matsui EC, et al. Clinical Tools to Assess Asthma Control in Children. *Pediatrics*. Jan 2017; 139(1). PMID 28025241
80. Khatri SB, Iaccarino JM, Barochia A, et al. Use of Fractional Exhaled Nitric Oxide to Guide the Treatment of Asthma: An Official American Thoracic Society Clinical Practice Guideline. *Am J Respir Crit Care Med*. Nov 15 2021; 204(10): e97-e109. PMID 34779751
81. Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. *Am J Respir Crit Care Med*. Sep 01 2011; 184(5): 602-15. PMID 21885636
82. Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. *Eur Respir J*. Jan 2020; 55(1). PMID 31558662
83. Cloutier MM, Baptist AP, Blake KV, et al. 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. *J Allergy Clin Immunol*. Dec 2020; 146(6): 1217-1270. PMID 33280709
84. National Heart Lung and Blood Institute. 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group 2020; <https://www.nhlbi.nih.gov/health-topics/all-publications-and-resources/2020-focused-updates-asthma-management-guidelines>. Accessed April 30, 2025.

CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

